Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?

References

• Rajashekar JL, Krishna D, Patil M. Polycystic ovaries and infertility: Our experience. Hum Reprod Sci 2008;1:65–72.
   PubMedGoogle Scholar
• Zawdaki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Toward a rationale approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications; 1992. pp 377–384.
   Google Scholar
• Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril 1999;71:319–322.
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Polycystic ovaries in Hirsute women with normal menses. Am J Med 2001;111:602–606.
   PubMed Web of Science ®Google Scholar
• Chang JR. Polycystic ovary syndrome: Diagnostic criteria. In: Chang RJ, Heindel JJ, Dunaif A, editors. Polycystic ovary syndrome. New York: Marcel Dekker; 2002. pp 361–365.
   Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.
   Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Hum Reprod 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Gorins A, Denis C. Effects of progesterone and progestational hormones on the mammary gland. Arch Anat Cytol Pathol 1995;43:28–35.
   PubMedGoogle Scholar
• Thalabard JC, Sitruk-Ware R, Kuttenn F, Mauvais-Jarvis P. Endocrine markers in benign breast diseases. Zentralbl Gynakol 1986;108:354–358.
   PubMedGoogle Scholar
• D’Amelio R, Farris M, Grande S, Feraudo E, Iuliano A, Zichella L. Association between polycystic ovary and fibrocystic breast disease. Gynecol Obstet Invest 2001;51:134–137.
   PubMed Web of Science ®Google Scholar
• Wiltgen D, Spritzer PM. Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes. Fertil Steril 2010;94:2493–2496.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: Purposes and pitfalls. Obstet Gynecol Surv 2004;59:141–154.
   PubMed Web of Science ®Google Scholar
• Devit J. Clinical benign disorders of the breast and carcinoma of the breast. Surg Gynecol Obstet 1981;152:437–440.
   PubMedGoogle Scholar
• Feig SA. The role of ultrasound in a breast imaging center. Semin Ultrasound CT MR 1989;10:90–105.
   PubMed Web of Science ®Google Scholar
• Hilton SV, Leopold GR, Olson LK, Willson SA. Real-time breast sonography: Application in 300 consecutive patients. AJR Am J Roentgenol 1986;147:479–486.
   PubMed Web of Science ®Google Scholar
• Gumus II, Koktener A, Dogan D, Turhan NO. Polycystic ovary syndrome and fibrocystic breast disease: Is there any association? Arch Gynecol Obstet 2009;280:249–253.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 1997;79:494–499.
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis P Sitruk-Ware R, Kutten F, Sterkers N. Luteal phase insufficiency: A common pathophysiological factor in development of benign and malignant breast disease. In: Bulbrook RD, Taylor DJ, editors Commentaries on research in breast disease. New York: Alan R. Liss; 1979. pp 25–29.
   Google Scholar
• Dogliotti L, Orlandi F, Angeli A. The endocrine basis of benign breast disorders. World J Surg 1989;13:674–679.
   PubMed Web of Science ®Google Scholar
• Sitruk-ware LR, Sterkers N, Mowszowicz I, Mauvais-Jarvis P. Inadequate corpus luteal function in women with benign breast diseases. J Clin Endocrinol Metab 1977;44:771–774.
   PubMed Web of Science ®Google Scholar
• von Fallois J, Etterli-Billenkamp U, Schindler EM, Schindler AE. Danazol for treatment of fibrocystic mastopathy. Zentralbl Gynakol 1995;117:457–465.
   PubMedGoogle Scholar
• Langer M, Kubista E, Schemper M, Spona J. Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch Gynecol Obstet 1990;247:203–209.
   PubMed Web of Science ®Google Scholar
• Wypych K, Kuzlik R, Wypych P. Hormonal abnormalities in women with breast cysts. Ginekol Pol 2002;73:1117–1125.
   PubMedGoogle Scholar
• Vetshev PS, Shkrob OS, Kuznetsov NS, Lotov AN, Kulezneva IuV, Beltsevich DG. Ultrasound diagnosis of breast nodules. Khirurgiia (Mosk) 1995;1:8–11.
   Google Scholar